camrelizumab

Home
Ligands
camrelizumab

GtoPdb Ligand ID: 9758

Synonyms: INCSHR1210 | SHR-1210

camrelizumab is an approved drug (China (2019))

Comment: Camrelizumab is a fully human anti-programmed cell death 1 (PD-1) monoclonal antibody being developed as an immuno-oncology therapeutic.

SARS-CoV-2 and COVID-19: Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 will be evaluated in clinical trial NCT04268537.

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Camrelizumab is another of the growing number of anti-PD-1 monoclonal antibodies being developed as immuno-oncology therapeutics, joining the already clinically approved anti-PD-1 mAbs pembrolizumab and nivolumab.

Immunopharmacology Comments

Camrelizumab is another of the growing number of anti-PD-1 monoclonal antibodies being developed as immuno-oncology therapeutics, joining the already clinically approved anti-PD-1 mAbs pembrolizumab and nivolumab.